E4Relief (Response to Estetrol in Life Improvement for MEnopausal-associated Hot Flushes) (NCT02834312) | Clinical Trial Compass
CompletedPhase 2
E4Relief (Response to Estetrol in Life Improvement for MEnopausal-associated Hot Flushes)
Belgium260 participantsStarted 2016-05
Plain-language summary
This dose-finding study is being conducted to select the daily oral dose of estetrol (E4) for the treatment of vasomotor symptoms (VMS) in post-menopausal women.
Who can participate
Age range40 Years – 65 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Women presenting at least 7 moderate to severe hot flushes/day or at least 50 moderate to severe hot flushes/week in the week preceding randomization.
* Body Mass Index (BMI) between 18.0 and 35.0 kg/m², inclusive.
* Post-menopausal status.
* Intact uterus.
* Negative pregnancy test.
* Good physical and mental health.
* Subject has provided signed and dated written informed consent before admission to the study.
* Subject is able to understand and comply with the protocol requirements, instructions, and protocol-stated restrictions.
Exclusion Criteria:
* Uterine disease or any medical conditions associated with an increase in endometrial thickness.
* Any history of malignancy with the exception of basal cell (excluded if within the prior 2 years) or squamous cell (excluded if within the prior one year) carcinoma of the skin. Any clinically significant findings at the breast examination and/or on mammography suspicious of breast malignancy that would require additional clinical testing to rule out breast cancer.
* Abnormal cervical Pap smear.
* Systolic blood pressure (BP) outside the range 90 to 140 mmHg, diastolic BP outside the range 60 to 90 mmHg, and/or heart rate outside the range 40 to 100 bpm.
* Any clinically significant abnormality identified on the screening 12-lead ECG.
* History of venous or arterial thromboembolic disease, history of known coagulopathy or abnormal coagulation factors.
* Diabetes mellitus with poor glycaemic control.
* Dys…
What they're measuring
1
Change in weekly frequency of moderate to severe VMS from baseline to week 4.
Timeframe: From baseline to week 4
2
Change in weekly frequency of moderate to severe VMS from baseline to week 12.
Timeframe: From baseline to week 12
3
Change in severity of moderate to severe VMS from baseline to week 4.
Timeframe: From baseline to week 4
4
Change in severity of moderate to severe VMS from baseline to week 12.